

Bruker Biosciences Pty Ltd Announces Establishment of Bruker Daltonics Mass Spectrometry Demonstration and Application Support Centre in Bio21 Institute Business Centre at University of Melbourne

Melbourne, Victoria, Australia—December 14, 2006 – Bruker Daltonics, a business unit of Bruker Biosciences Pty Ltd., today announced that it has established a mass spectrometry demonstration and application support centre for the Australian and New Zealand markets at the Bio21 Institute Business Centre, University of Melbourne.



Bruker Daltonics is a leading supplier of enabling technologies based on Mass Spectrometry for life science, pharmaceutical, biochemical and chemical research. Its innovative products include a complete range of MALDI-TOF, MALDI-TOF/TOF, FTMS, ESI-Ion Trap, ESI-LC/TOF, and ESI-Q-q-TOF systems, as well as a complete line of automated sample processing systems and productivity-enhancing software designed to deliver meaningful scientific data.



The company has been increasingly successful in the Australian market since its establishment in January 2001 and has developed a growing presence in the fields of proteomics, small molecules and clinical solutions research.

The new centre, headed by Dr Matthias Pelzing, Asia Pacific Region Applications Manager for Bruker Daltonics, offers advanced application training and demonstration of the power of the company's technical solutions based on its extensive range of mass spectrometers. The facility also offers access to state of the art systems and technologies to the members of Australia's academic community as part of a technology collaboration designed to further technology transfer and the community's research outcomes.

“ This applications centre will provide our customers with access to the highest quality application training in conjunction with an opportunity for us to showcase our innovative



mass spectrometry based technical solutions to Australian and New Zealand scientists,” commented Clive Seymour, Vice President of Bruker Daltonics Asia Pacific and Managing Director of Bruker Biosciences Pty Ltd. “We are excited to be associated with this leading institution and to be able

to also contribute further to the research aims of the Australian scientific community.”

Bio21 Institute Director, Professor Dick Wettenhall, observed, “The location of the state-of-the-art Bruker Biosciences facility within the Bio21 Business Centre will provide further opportunities for developing close collaborations between industry and academia, which has been one of the major objectives of the Bio21 Project from the outset.”

For Further Information:

Clive Seymour
Managing Director Bruker Biosciences Pty Ltd
Tel: +64 21 640 801
Email: chs@bdal.com